MarketCatalyst
← Back to Research
Earnings

Artivion Beats Q3 2026 Estimates as Revenue Rises 9.2% to $123.8M

Revenue of $123.8M vs. $121.0M expected and adjusted EPS of $0.08 vs. -$0.06; revenue up 9.2% from a year earlier.

Published Nov 5, 2026 · 4:07 PM ET · 2 min read

Artivion (AORT) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $123.8 million, up 9.2% from a year earlier, above the $121.0 million estimate, and adjusted EPS was $0.08, down 50% from a year earlier, above the -$0.06 estimate.

Shares rose 0.2% in after-hours trading as of 4:02 p.m. ET, to $25.33 from a $25.29 close.

$0.08
Adjusted EPS, down 50% YoY vs. -$0.06 estimate
$123.8M
Revenue, up 9.2% YoY vs. $121.0M estimate
+0.2%
Shares after hours as of 4:02 p.m. ET

Q3 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS-$0.06$0.08Beat by 231%
Revenue$121.0M$123.8MBeat by 2.3%
ChangeYoYQoQ
Adjusted EPS▼ 50%▲ from -$0.28
Revenue▲ 9.2%▼ 1.6%

By our calculation, revenue was $2.8 million above the estimate and adjusted EPS was $0.14 above it. The QoQ column compares with the previous quarter's revenue of $125.8 million and adjusted EPS of -$0.28. The YoY column compares with $113.4 million and $0.16 in the same quarter a year earlier.

Track record

  • EPS record. Adjusted EPS beat the estimate in 2 of the last 8 reports, including this one.
  • Revenue record. Revenue beat the estimate in 6 of the last 8 reports.
  • Revenue trend. Revenue over the last 5 reports, oldest first: $113.4 million, $116.0 million, $116.3 million, $125.8 million and $123.8 million.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of $0.05 and revenue of $128.7 million next quarter, based on 3 analysts.
  • Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 9.2% increase to $123.8 million.
  • Estimate record. Whether Artivion returns to beating EPS estimates, which it did in 2 of its last 8 reports.
  • Related coverage. See our reports on Yelp, 10x Genomics, Tandem Diabetes Care and Savers Value Village.

Sources: Results are from Artivion's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Artivion's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.